Can MarketClub's Trade Triangle Technology Predict Earnings?

Today, I'm going to investigate whether or not MarketClub's Trade Triangle technology can predict stock earnings.

To do this I randomly chose 7 stocks that just reported their Q3 earnings. Here are the rules I followed for taking or not taking a position in a stock before a company announced its earnings.

Long And Short Rules

Use the Trade Triangle technology to determine how you would have been positioned in each stock before they announced their earnings. You are looking for uniformity between the monthly and weekly Trade Triangles, i.e. a matching monthly and weekly green Trade Triangle would indicate holding a long position before an earnings announcement. Conversely, a matching monthly and weekly red Trade Triangle would indicate holding a short position before an earnings announcement.

Sideline Rules

When there is a conflict between the weekly and monthly Trade Triangles, a sideline position is in order. For example, if a monthly Trade Triangle is green and the weekly Trade Triangle is red, it would indicate a sideline position.

Here are 7 stocks that just announced their earnings: Continue reading "Can MarketClub's Trade Triangle Technology Predict Earnings?"

Here's One Stock That Could Do Very Well In Q4

There are two months left in the quarter and the Fed continues to dither, and if anything, create uncertainty in the marketplace. I read this morning there's a 52% chance that they will raise interest rates in December. That means there is also a 48% chance that they will not raise interest rates in December. This uncertainty and lack of direction from the Fed is causing anxiety problems for the market.

That aside, I do have a stock that I think will do well for the balance of the year. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) had a monthly green Trade Triangle trigger yesterday. The stock has the potential to move up as much as 20% in the next several months. In today's video, I'll show you why I think it can move up 20% from current levels. I will also share with you an important technical aspect that makes me believe that this can happen this quarter or early in Q1 of 2016. Continue reading "Here's One Stock That Could Do Very Well In Q4"

This Stock Could Outperform The Market In The Next Three Months

October proved to be a spectacular month for stocks with the best gains seen since the third quarter of 2011. Historically, the last quarter proves to be a good one for stocks. That is not a guarantee that stocks will go higher, but historically since 1949, stocks have averaged a gain of 4% in Q4. That is followed by a strong Q1 with the average gain of 2%. History is all well and good, but it doesn't necessarily repeat itself in a very systematic fashion every single year.

Here's the stock that I think can do very well in Q4. The stock is TE Connectivity Ltd. (NYSE:TEL). Presently this stock is trading around the $64.90 area and I believe it can move substantially higher in Q4.

Here are the reasons why I think that: Continue reading "This Stock Could Outperform The Market In The Next Three Months"

Spotting Breakouts That Lead To Trend Reversals

We get a lot of questions here at INO.com about how to spot breakouts before they occur. As a treat to our Trader's Blog readers we have asked Darell Jobman, a leading expert in technical analysis to share some his techniques. 

In this video workshop you'll discover how putting indicator clues together to identify setups for a new trend. Darrell has been writing about financial markets for more than 35 years and has become an acknowledged authority on derivative markets, technical analysis and various trading techniques.

Watch Now:Spotting Breakouts That Lead To Trend Reversals

Best,
The INOTV Team

Did Bill Ackman Get Valeant (VRX) Wrong?

There is a lot of talk today about the stock Valeant Pharmaceuticals International Inc. (NYSE:VRX) from one of its largest shareholders, Bill Ackman. You may remember Mr. Ackman from his ill-fated forays into JCPenney, Herbalife and Target.

Today he is defending (via a conference call) one of his biggest investments in Canadian pharmaceutical company, Valeant. This stock was very instrumental in helping Mr. Ackman's Pershing Square Capital be the best-performing hedge fund last year, with a return of 40.4%. This year it's another story as this stock has tanked and Pershing has a reported paper loss of 1.5 billion dollars. Allegations of impropriety and finagling its sales and the way it does business have all contributed to Valeant's slide in the marketplace. Continue reading "Did Bill Ackman Get Valeant (VRX) Wrong?"